Sirtuin modulating compounds

• US 8,093,401 B2
• Filed: 08/04/2006
• Issued: 01/10/2012
• Est. Priority Date: 08/04/2005
• Status: Expired due to Fees

• Current Assignee: Sirtris Pharmaceuticals, Inc. (GlaxoSmithKline PLC)
• Original Assignee: Sirtris Pharmaceuticals, Inc. (GlaxoSmithKline PLC)
• Inventors: Nunes, Joseph J., Milne, Jill, Bemis, Jean, Xie, Roger, Vu, Chi B., Ng, Pui Yee, Disch, Jeremy S.
• Primary Examiner(s): HAVLIN, ROBERT H
• Application Number:
  US11/499,239
• Publication Number:
  US 20070037827A1
• Time in Patent Office: 1,985 Days
• Field of Search: 548/309.7, 514/393
• US Class Current: 548/309.7
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Claims

1. A compound of the formula:

5. The compound according to claim 1, wherein R²⁵ is selected from H, —

CH₂—

N(CH₃)₂ and

6. The compound according to claim 1, wherein R²³ and R²⁴ are H.

7. The compound according to claim 1, wherein R¹⁹ is substituted with:

a) up to three —

O—

CH₃ groups;

or

b) one —

N(CH₃)₂ group.

8. The compound according to claim 1, wherein R²¹ is —

NH—

C(0)—

.

2. A composition comprising a compound of the formula:

3. A pharmaceutical composition comprising:

a) a compound of the formula;

4. A packaged pharmaceutical comprising a compound of the formula: